NRXS vs. TELA, HYPR, NSPR, CTCX, SRTS, ZYXI, CTSO, RBOT, MDAI, and SURG
Should you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include TELA Bio (TELA), Hyperfine (HYPR), InspireMD (NSPR), Carmell (CTCX), Sensus Healthcare (SRTS), Zynex (ZYXI), Cytosorbents (CTSO), Vicarious Surgical (RBOT), Spectral AI (MDAI), and SurgePays (SURG). These companies are all part of the "medical equipment" industry.
NeurAxis vs. Its Competitors
TELA Bio (NASDAQ:TELA) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.
TELA Bio has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.09, indicating that its share price is 209% more volatile than the S&P 500.
TELA Bio has a net margin of -61.00% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat TELA Bio's return on equity.
In the previous week, TELA Bio had 5 more articles in the media than NeurAxis. MarketBeat recorded 5 mentions for TELA Bio and 0 mentions for NeurAxis. TELA Bio's average media sentiment score of 0.39 beat NeurAxis' score of 0.00 indicating that TELA Bio is being referred to more favorably in the media.
NeurAxis has lower revenue, but higher earnings than TELA Bio. NeurAxis is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.
94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by company insiders. Comparatively, 15.2% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
TELA Bio presently has a consensus price target of $7.25, indicating a potential upside of 271.79%. NeurAxis has a consensus price target of $7.00, indicating a potential upside of 153.62%. Given TELA Bio's higher possible upside, analysts plainly believe TELA Bio is more favorable than NeurAxis.
Summary
TELA Bio beats NeurAxis on 9 of the 16 factors compared between the two stocks.
Get NeurAxis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeurAxis Competitors List
Related Companies and Tools
This page (NASDAQ:NRXS) was last updated on 7/24/2025 by MarketBeat.com Staff
